Sensei Biotherapeutics Inc - Asset Resilience Ratio
Sensei Biotherapeutics Inc (SNSE) has an Asset Resilience Ratio of 24.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Sensei Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Check Sensei Biotherapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sensei Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Sensei Biotherapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.47 Million | 24.57% |
| Total Liquid Assets | $50.47 Million | 24.57% |
Asset Resilience Insights
- Good Liquidity Position: Sensei Biotherapeutics Inc maintains a healthy 24.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sensei Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sensei Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Sensei Biotherapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Sensei Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.65% | $12.52 Million | $22.90 Million | -14.44pp |
| 2024-12-31 | 69.09% | $31.34 Million | $45.36 Million | -1.83pp |
| 2023-12-31 | 70.92% | $52.75 Million | $74.37 Million | -4.54pp |
| 2022-12-31 | 75.46% | $89.32 Million | $118.38 Million | -16.21pp |
| 2021-12-31 | 91.67% | $140.46 Million | $153.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $21.43 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more